Perrigo Company plc Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Perrigo Company plc (PRGO) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $4.95 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-03-01
- Perrigo Company plc sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2015-12-31 was $1.42B, a 32.95% increase year-over-year.
- Perrigo Company plc sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2015-09-26 was $1.34B, a 41.32% increase year-over-year.
- Perrigo Company plc sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2015-06-27 was $1.53B, a 33.86% increase year-over-year.
- Perrigo Company plc sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2015-03-28 was $1.05B, a 4.47% increase year-over-year.
- Perrigo Company plc sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $4.95B, a 6.33% decline from fiscal 2016.
- Perrigo Company plc sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $5.28B.
- Perrigo Company plc sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $4.23B, a 4.10% increase from fiscal 2014.
- Perrigo Company plc sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $4.06B, a 14.72% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2017-12-31 | $4.95B 10-K · filed 2018-03-01 | |||||
| 2016-12-31 | $5.28B 10-K · filed 2018-03-01 | |||||
| 2015-12-31 | $1.42B 10-KT · filed 2016-02-25 | $2.63B 10-K · filed 2018-03-01 | $2.77B 10-KT · filed 2016-02-25 | $4.30B derived: sum of 3 quarters · filed 2016-02-25 | $5.35B derived: sum of 4 quarters · filed 2016-02-25 | |
| 2015-09-26 | $1.34B 10-KT · filed 2016-02-25 | $2.88B derived: sum of 2 quarters · filed 2016-02-25 | $3.93B derived: sum of 3 quarters · filed 2016-02-25 | $5.00B derived: sum of 4 quarters · filed 2016-02-25 | ||
| 2015-06-27 | $1.53B 10-KT · filed 2016-02-25 | $2.58B derived: sum of 2 quarters · filed 2016-02-25 | $3.65B derived: sum of 3 quarters · filed 2016-02-25 | $4.23B 10-K · filed 2018-03-01 | $4.60B 10-K · filed 2015-08-13 | |
| 2015-03-28 | $1.05B 10-KT · filed 2016-02-25 | $2.12B derived: sum of 2 quarters · filed 2016-02-25 | $3.07B derived: sum of 3 quarters · filed 2016-02-25 | $4.22B derived: sum of 4 quarters · filed 2016-02-25 | ||
| 2014-12-27 | $1.07B 10-KT · filed 2016-02-25 | $2.02B 10-KT · filed 2016-02-25 | $3.17B derived: sum of 3 quarters · filed 2016-02-25 | $4.17B derived: sum of 4 quarters · filed 2016-02-25 | ||
| 2014-09-27 | $951.50M 10-KT · filed 2016-02-25 | $2.10B derived: sum of 2 quarters · filed 2016-02-25 | $3.10B derived: sum of 3 quarters · filed 2016-02-25 | $4.08B derived: sum of 4 quarters · filed 2016-02-25 | ||
| 2014-06-28 | $1.14B 10-KT · filed 2016-02-25 | $2.15B derived: sum of 2 quarters · filed 2016-02-25 | $3.13B derived: sum of 3 quarters · filed 2016-02-25 | $4.06B 10-KT · filed 2016-02-25 | ||
| 2014-03-29 | $1.00B 10-KT · filed 2016-02-25 | $1.98B derived: sum of 2 quarters · filed 2016-02-25 | $2.92B derived: sum of 3 quarters · filed 2016-02-25 | |||
| 2013-12-28 | $979.00M 10-KT · filed 2016-02-25 | $1.91B derived: sum of 2 quarters · filed 2016-02-25 | ||||
| 2013-09-28 | $933.40M 10-KT · filed 2016-02-25 | |||||
| 2013-06-29 | $3.54B 10-KT · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |